|Bid||2.7300 x 21500|
|Ask||2.7400 x 3200|
|Day's Range||2.4500 - 2.7600|
|52 Week Range||0.8700 - 6.9300|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -40.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment of chronic HBV infection. The open-label study is designed to evaluate the safety and efficacy of BRII-835 (VIR-2218) compared to the combination of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with and without interferon-alpha as a co-adjuvant. Brii Bio has led the design and implementation of this functional cure proof-of-concept study and is the sponsor of the Phase 2 study. BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. VBI-2601 (BRII-179) is a recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI's prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity. Price Action: VBIV shares 1.9% at $2.66, while VIR shares are down 1.9% at $47.5 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTrevena's TRV027 Included In Global COVID-19 StudyHouse Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.